In Colombia, a laboratory-based surveillance of invasive Streptococcus pneumoniae isolates as part of SIREVA II PAHO has been conducted since 1994. This study describes the serotype distribution, antimicrobial resistance, and genetic relationships of pneumococcal isolates recovered in Colombia from 2005 to 2010. In this study, demographic data of invasive S. pneumoniae isolates were analyzed, and antimicrobial susceptibility patterns were determined. Pulse field gel electrophoresis (n = 629) and multilocus sequence typing (n = 10) were used to determine genetic relationship of isolates with minimal inhibitory concentration to penicillin ≥0.125 μg/mL. A total of 1775 isolates of S. pneumoniae were obtained. Fifteen serotypes accounted for 80.7% of isolates. Serotype 14 (23.1%) was the most frequent in the general population. Penicillin resistance was 30.7% in meningitis and 9.0% in non-meningitis. Clones Spain6BST90, Spain9VST156, Spain23FST81, and Colombia23FST338 were associated to isolates. Additionally, serotype 6A isolates were associated with ST460 and ST473, and 19A isolates with ST276, ST320, and ST1118. In conclusion, the surveillance program provided updated information of trends in serotype distribution, antimicrobial resistance and the circulation of clones in invasive pneumococcal diseases. These results could be helpful to understand the epidemiology of S. pneumoniae in Colombia, and provide a baseline to measure the impact of vaccine introduction.
References
[1]
Lynch JP, Zhanel GG (2010) Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 16: 217–25.
[2]
Calix JJ, Nahm MH (2010) A new pneumococcal serotype, 11E, has a variably inactivated wcjE Gene. J Infect Dis 202: 29–38.
[3]
Calix JJ, Porambo RJ, Brady AM, Larson TR, et al. (2012) Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains: Discovery of a new pneumococcal serotype. J Biol Chem 287: 27885–94.
[4]
Ko KS, Baek JY, Song JH (2013) Capsular Gene Sequences and Genotypes of “Serotype 6E” Streptococcus pneumoniae Isolates. J Clin Microbiol 51: 3395–9.
[5]
Oliver MB, van der Linden MP, Küntzel SA, Saad JS, Nahm MH (2013) Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem 288: 25976–85.
Tan TQ (2012) Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 25: 409–19.
[8]
Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962–73.
[9]
Reinert RR (2009) The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 15 Suppl 37–11.
[10]
Henriques-Normark B, Blomberg C, Dagerhamn J, Battig P, Normark S (2008) The rise and fall of bacterial clones: Streptococcus pneumoniae. Nat Rev Microbiol 6: 827–837.
[11]
Ministerio de la Protección Social. Acuerdo Número 406 de 2009. Available: www.dssa.gov.co/index.php/./doc./460-acu？erdo-406-neumococo. Accessed 13 November 2012.
[12]
Ministerio de Salud y Protección Social. Jornada de Vacunación en Las Americas 2012. Available: http://www.minsalud.gov.co/Lineamientos/？Documento_Marco_Jornada_de_Vacunacion_de？_las_Am%C3%A9ricas_abril2012.pdf. Accessed 13 November 2012.
[13]
Agudelo CI, Moreno J, Sanabria OM, Ovalle MV, Di Fabio JL, et al. (2006) Streptococcus pneumoniae: evolución de los serotipos y los patrones de susceptibilidad antimicrobiana en aislamientos invasores en 11 a？os de vigilancia en Colombia (1994–2004). Biomédica 26: 234–49.
[14]
Parra EL, De La Hoz F, Díaz PL, Sanabria O, Realpe ME, et al. (2013) Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia. Vaccine 31: 4033–8.
[15]
Clinical Laboratory Standards Institute (2010) Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement. CLSI document M100-S21. Wayne, PA: CLSI.
[16]
Vela MC, Fonseca N, Di Fabio JL, Casta？eda E, et al. (2001) Presence of international multiresistant clones of Streptococcus pneumoniae in Colombia. Microb Drug Resist. 7: 153–64.
[17]
Enright M, Spratt BG (1998) A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144: 3049–60.
[18]
Aanensen DM, Spratt BG (2005) The multilocus sequence typing network: mlst.net Nucleic Acids Res. Web Server issue: W728–33. Available: http://spneumoniae.mlst.net/. Accessed 15 July 2013.
[19]
Constenla D, Gomez E, de la Hoz FP, O’Loughlin R, Sinha A, et al.. (2007) The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis. Report. Washington, DC: A collaborative project of: The Albert B. Sabin Vaccine Institute, Pan American Health Organization, GAVI’s Pneumococcal Accelerated Development and Introduction Plan at Johns Hopkins (PneumoADIP) Centers for Disease Control and Prevention. Available: http://www.ispch.cl/sites/default/files/？document1.pdf). Accessed 05 September 2013.
Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J (2006) Attenuated cerebrospinal fluid leukocyte count and sepsis in adults with pneumococcal meningitis: a prospective cohort study. BMC Infect Dis 6: 149.
[22]
Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 30: 100–21.
[23]
Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Hance F, et al.. (2010) Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 7. doi:pii: e1000348.
[24]
Horácio AN, Diamantino-Miranda J, Aguiar SI, Ramirez M, Melo-Cristino J (2012) Serotype changes in adult invasive pneumococcal infections in Portugal did not reduce the high fraction of potentially vaccine preventable infections. Vaccine 30: 218–224.
[25]
Scott JA, Hall AJ, Dagan R, Dixon JM, Eykyn SJ, et al. (1996) Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis 22: 973–81.
[26]
Sj？str？m K, Blomberg C, Fernebro J, Dagerhamn J, Morfeldt E, et al. (2007) Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci USA 104: 12907–12.
[27]
Pletz MW, McGee L, Jorgensen J, Beall B, Facklam RR, et al. (2004) Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 48: 3491–7.
[28]
Reinert RR, Ringelstein A, van der Linden M, Cil MY, Al-Lahham A, et al. (2005) Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe. J Clin Microbiol 43: 1294–300.
[29]
Hiller NL, Eutsey RA, Powell E, Earl JP, Janto B, et al. (2011) Differences in genotype and virulence among four multidrug-resistant Streptococcus pneumoniae isolates belonging to the PMEN1 clone. PLoS One. 6: e28850.
[30]
Baek JY, Ko KS, Kim SH, Kang CI, Chung DR, et al. (2011) Comparison of genotypes of Streptococcus pneumoniae serotypes 6A and 6B before and after the introduction of PCV7 vaccination in Korea. Diagn Microbiol Infect Dis. 69: 370–5.
[31]
Sá-Le？o R, Tomasz A, Sanches IS, Brito-Av？ A, Vilhelmsson SE, et al. (2000) Carriage of internationally spread clones of Streptococcus pneumoniae with unusual drug resistance patterns in children attending day care centers in Lisbon, Portugal. J Infect Dis 182: 1153–60.
[32]
Hsieh YC, Huang YC, Lin HC, Ho YH, Chang KY, et al. (2009) Characterization of invasive isolates of Streptococcus pneumoniae among Taiwanese children. Clin Microbiol Infect 15: 991–6.
[33]
Serrano I, Melo-Cristino J, Carri？o JA, Ramirez M (2005) Characterization of the genetic lineages responsible for pneumococcal invasive disease in Portugal. J Clin Microbiol 43: 1706–15.
[34]
Gherardi G, D’Ambrosio F, Visaggio D, Dicuonzo G, Del Grosso M, et al. (2012) Serotype and clonal evolution of penicillin-nonsusceptible invasive Streptococcus pneumoniae in the 7-valent pneumococcal conjugate vaccine era in Italy. Antimicrob Agents Chemother 56: 4965–8.
[35]
Gherardi G, Brueggemann AB, Pai R, Crook DW, Beall B (2007) Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 3: e168.
[36]
Reinert R, Jacobs MR, Kaplan SL (2010) Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28: 4249–59.
[37]
Casta？eda E, Agudelo CI, De Antonio R, Rosselli D, Calderón C, et al. (2012) Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010. BMC Infect Dis 12: 124.
[38]
Aguiar SI, Pinto FR, Nunes S, Serrano I, Melo-Cristino J, et al. (2010) Denmark14–230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol 48: 101–8.
[39]
Mahjoub-Messai F, Doit C, Koeck JL, Billard T, Evrard B, et al. (2009) Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal Vaccination for French children. J Clin Microbiol 47: 837–40.
[40]
Mu？oz-Almagro C, Ciruela P, Esteva C, Marco F, Navarro M, et al. (2011) Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect. 63: 151–62.
[41]
Pillai DR, Shahinas D, Buzina A, Pollock RA, Lau R, et al. (2009) Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics 10: 642.
[42]
Shin J, Baek JY, Kim SH, Song JH, Ko KS (2011) Predominance of ST320 among Streptococcus pneumoniae serotype 19A isolates from 10 Asian countries. J Antimicrob Chemother 66: 1001–4.
[43]
Rolo D, Fenoll A, Ardanuy C, Calatayud L, Cubero M, et al. (2011) Trends of invasive serotype 6C pneumococci in Spain: emergence of a new lineage. J Antimicrob Chemother 66: 1712–8.
[44]
Carvalho Mda G, Pimenta FC, Gertz RE Jr, Joshi HH, Trujillo AA, et al. (2009) PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 47: 554–9.
[45]
SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables de Neumonias y Meningitis Bacterianas. Informe Regional de SIREVA II, (2012). Available: http://new.paho.org/hq/index.php?option=？com_content&view=category&layout=blog&id？=3609&Itemid=3953&lang=. Accessed, 02 September 2013.
[46]
Leal J, Vanderkooi OG, Church DL, Macdonald J, Tyrrell GJ, et al. (2012) Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta. Pediatr Infect Dis J 31: e169–75.
[47]
Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, et al. (2011) Epidemiology of Streptococcus pneumonia in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 30: 1511–19.
